Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

James Cottom

Podiatrist Sarasota, FL Doctor of Podiatric Medicine

NPI 1720079163 CMS profile 924838

5741 Bee Ridge Rd Ste 490, Sarasota, FL 34233

Open in the dashboard

General payments

$1,758,666

740 records reported · program years 2019–2025

Research payments

$42,780

Paid to them · 10 records reported · program years 2019–2025

Ownership & investment interest

$187,763

8 holdings reported · through program year 2025

Research they led as principal investigator

$54,438 paid to institutions, not to them · program years 2021–2025

Through program year 2025, James Cottom of Sarasota, FL is reported in the CMS Open Payments database as having received $1,758,666 across 740 general payments and $42,780 in research payments paid to them. Separately, studies naming them as principal investigator received $54,438 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $187,763 across 8 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Podiatrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

16 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $240,717 90
2024 General $327,987 124
2023 General $468,511 113
2022 General $261,760 101
2021 General $204,368 122
2020 General $129,314 76
2020 Research $12,288 4
2019 General $126,009 114
2019 Research $30,492 6
2025 Ownership $37,763 2
2024 Ownership $25,000 1
2023 Ownership $25,000 1
2022 Ownership $25,000 1
2021 Ownership $25,000 1
2020 Ownership $25,000 1
2019 Ownership $25,000 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Cottom
  • Podiatrist median
  • Middle half of Podiatrist
  • National median

In program year 2025, general payments to James Cottom were reported at $240,717. Among 4,572 Podiatrist profiles paid that year, the median was $260 and the middle half received between $94 and $777.

Show as a table
Year James Cottom Podiatrist median Middle half National median
2019 $126,009 $196 $72–$601 $163
2020 $129,314 $118 $38–$335 $114
2021 $204,368 $169 $57–$573 $132
2022 $261,760 $220 $74–$782 $149
2023 $468,511 $208 $71–$635 $160
2024 $327,987 $237 $87–$681 $164
2025 $240,717 $260 $94–$777 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Arthrex, Inc. $890,220 290 payments
  2. Vilex in Tennessee, Inc. $444,801 168 payments
  3. Kerecis Limited $104,465 54 payments
  4. Triad Life Sciences Inc. $94,812 34 payments
  5. Fusion Orthopedics USA, LLC $38,116 9 payments
  6. Integra LifeSciences Corporation $33,750 23 payments
  7. restor3d, inc. $32,825 15 payments
  8. OSSIO Inc. $25,217 3 payments
  9. Organogenesis Inc. $24,346 24 payments
  10. International Life Sciences $20,821 8 payments
  11. Other $49,294 112 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Royalty or License $674,827 76 payments
  2. Consulting Fee $626,004 198 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $157,718 35 payments
  4. Travel and Lodging $133,140 165 payments
  5. Compensation for serving as faculty or as a speaker for a medical education program $108,923 17 payments
  6. Acquisitions $27,248 4 payments
  7. Food and Beverage $14,008 238 payments
  8. Current or prospective ownership or investment interest $9,600 1 payment
  9. Education $6,200 5 payments
  10. Honoraria $1,000 1 payment
Products named General payments · program years 2019–2025
  1. Arthrex Foot & Ankle and Trauma - Implants - Soft Tissue - Tenodesis - Tension Slide $441,074 16 payments
  2. HINTERMANN $335,040 89 payments
  3. ARTHREX Distal Extremities - Implants - Trauma - Jones Fracture $215,736 8 payments
  4. ARTHREX Distal Extremities - Implants - Soft Tissue - Tenodesis $215,736 8 payments
  5. ARTHREX Distal Extremities - Implants - Soft Tissue - Tenodesis $215,736 8 payments
  6. ARTHREX Distal Extremities - Implants - Soft Tissue - Tenodesis $215,736 8 payments
  7. ARTHREX Distal Extremities - Instruments - Soft Tissue - Disposable Kits $160,746 6 payments
  8. Arthrex Extremities & Trauma - Implants - Soft Tissue - Tenodesis $125,957 4 payments
  9. Arthrex Extremities & Trauma - Implants - Soft Tissue - Tenodesis $125,957 4 payments
  10. Arthrex Extremities & Trauma - Implants - Soft Tissue - Tenodesis $125,957 4 payments
  11. Other $2,290,882 697 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Integra LifeSciences Corporation $25,130 8 payments
  2. Avitus Orthopaedics, Inc. $17,650 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

135

Median for Podiatry: 160

Drug cost

$1,287

Median for Podiatry: $2,368

Branded share of claims

48.9%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 54 $809
Ondansetron Hcl Generic 38 $222
Cephalexin Generic 31 $216
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 12 $39

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 100 billing codes

Paid by Medicare

$166,074

Of which drugs: $165

Medicare patients

288

Average age 74

Services billed

2,299

171 women, 117 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 73%
Ischemic heart disease 34%
Diabetes 27%
Depression 22%
Osteoporosis 22%
Chronic kidney disease 20%
Atrial fibrillation 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 29 225 $159

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

750 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record